Mylan N.V. (NASDAQ:MYL) had its target price increased by Morgan Stanley from $36.00 to $39.00 in a research report released on Friday. The firm currently has an equal weight rating on the stock.

A number of other research analysts have also issued reports on MYL. Cowen and Company reiterated a hold rating and issued a $30.00 target price (down from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 target price on Mylan N.V. and gave the company a hold rating in a report on Wednesday, August 9th. Wells Fargo & Company set a $30.00 target price on Mylan N.V. and gave the company a hold rating in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a sector perform rating and issued a $32.00 target price (down from $33.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Finally, BMO Capital Markets reiterated an outperform rating and issued a $45.00 target price (down from $50.00) on shares of Mylan N.V. in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $41.99.

Shares of Mylan N.V. (MYL) opened at 38.29 on Friday. The stock has a market capitalization of $20.53 billion, a PE ratio of 30.95 and a beta of 1.30. The company’s 50 day moving average price is $32.08 and its 200-day moving average price is $36.45. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87.

Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the business posted $1.16 earnings per share. Equities research analysts predict that Mylan N.V. will post $4.57 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Mylan N.V. (MYL) Price Target Raised to $39.00” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/09/mylan-n-v-myl-price-target-raised-to-39-00.html.

Institutional investors have recently bought and sold shares of the company. Global X Management Co. LLC increased its position in Mylan N.V. by 91.6% in the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after acquiring an additional 1,441 shares during the period. TLP Group LLC acquired a new position in Mylan N.V. in the 1st quarter valued at about $200,000. Doliver Capital Advisors LP acquired a new position in Mylan N.V. in the 2nd quarter valued at about $201,000. Eagle Global Advisors LLC acquired a new position in Mylan N.V. in the 2nd quarter valued at about $205,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in Mylan N.V. in the 2nd quarter valued at about $210,000. 71.97% of the stock is owned by institutional investors and hedge funds.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.